Thus, Navas Rodrigues and coworkers have shown that up to 8% of mCRPC have evidence for defective MMR, associated with loss of some MMR effectors, such as MSH2, MSH6, MLH1, or PMS2; dMMR was associated with poor overall survival compared to MMR-proficient prostate tumors (3.8 versus 7.0 years) [154]. Here, MRC1 is linked to prostate neoplasm.